Orforglipron
Also known as: LY3502970
Investigational Compound. This compound is currently in clinical development and has not received regulatory approval. No established commercial regimen exists. Consult a qualified clinician for the latest information on clinical trial availability.
Overview
Clinical Summary
Orforglipron (LY3502970) is an oral, non-peptide small molecule GLP-1 receptor agonist under development by Eli Lilly. Unlike oral semaglutide (Rybelsus), which is a peptide requiring fasting and specific administration conditions to achieve adequate bioavailability, orforglipron is a small molecule that can be taken without food or water restrictions. Phase 2 data have demonstrated clinically meaningful weight loss and glycemic improvements. Orforglipron is currently in Phase 3 development for both obesity and type 2 diabetes. If approved, it would represent the first oral non-peptide GLP-1RA, potentially transforming the accessibility and convenience of incretin-based therapy.
Plain Language Summary
Orforglipron is an investigational pill being developed by Eli Lilly that works on the same GLP-1 pathway as injectable medications like Ozempic. What makes it notable is that it is a true small molecule (not a peptide) that can be swallowed with or without food and without the fasting restrictions required by the current oral GLP-1 pill (Rybelsus). In studies, people taking orforglipron lost about 14.7% of their body weight. It is currently in late-stage trials and, if approved, could make this class of medication much more accessible to people who prefer pills over injections.
Mechanism of Action
Orforglipron is a non-peptide, small molecule agonist of the GLP-1 receptor. It binds to an allosteric site on the GLP-1R, inducing a conformational change that mimics the effects of the native peptide ligand. This results in downstream signaling through Gs-coupled cAMP pathways, leading to glucose-dependent insulin secretion, glucagon suppression, appetite reduction, and delayed gastric emptying. As a small molecule, orforglipron does not require the absorption-enhancing excipients (such as SNAC in oral semaglutide) needed for peptide oral bioavailability. It has an oral bioavailability that enables once-daily dosing without fasting requirements. The half-life is approximately 25 to 36 hours, supporting daily administration.
Evidence Summary
A Phase 2 trial in 272 adults with overweight/obesity without T2D (Wharton et al., NEJM 2023) showed dose-dependent weight loss of up to 14.7% at 36 weeks. A parallel Phase 2 trial in 383 adults with T2D (Frias et al., NEJM 2023) demonstrated HbA1c reductions of up to 2.1% and weight loss of up to 7.9 kg at 26 weeks. No fasting or water restriction was required. Phase 3 trials (ACHIEVE program for T2D, ATTAIN program for obesity) are underway. Limitations include Phase 2 data only, relatively short trial durations (26 to 36 weeks), and absence of cardiovascular outcomes data. Direct comparisons with injectable GLP-1RAs are pending.
Safety Profile
The Phase 2 safety profile was consistent with the GLP-1RA class. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common and were dose-dependent. Severity was generally mild to moderate, with most events occurring during dose escalation. Discontinuation rates due to adverse events ranged from 5 to 17% across dose groups. No pancreatitis events were reported. No thyroid C-cell signals were identified, though exposure duration was limited. As a non-peptide molecule, immunogenicity (anti-drug antibodies) is not expected to be a concern, which is an advantage over injectable peptide GLP-1RAs.
Contraindications
- Personal or family history of medullary thyroid carcinoma (GLP-1RA class precaution pending label)
- Multiple endocrine neoplasia type 2
- Known hypersensitivity to orforglipron or excipients
- Pregnancy (insufficient safety data)
Adverse Events
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Constipation
- Dyspepsia
- Decreased appetite
Interactions
- May delay gastric emptying, potentially affecting absorption of concomitant oral medications
- Caution with insulin or sulfonylureas (increased hypoglycemia risk)
- No formal drug-drug interaction studies have been published; Phase 3 trials may include PK substudies
Regulatory Notes
Orforglipron is in Phase 3 development by Eli Lilly and Company. It has not received FDA or EMA approval. The Phase 3 program includes ACHIEVE (T2D) and ATTAIN (obesity) trial series. If approved, it would be the first oral non-peptide GLP-1RA. The potential for simplified manufacturing (chemical synthesis vs. biologic peptide production) and oral delivery without fasting restrictions could significantly improve accessibility and reduce cost compared to injectable GLP-1RAs and oral semaglutide.
Monitoring Considerations
Monitor HbA1c, fasting glucose, and body weight at regular intervals. Assess GI tolerability during dose titration. Monitor for signs and symptoms of pancreatitis. Thyroid monitoring per GLP-1RA class precautions. Renal function monitoring is advisable given the potential for dehydration from GI adverse events. As clinical development matures, additional monitoring parameters may be identified.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Investigational product. As a small molecule, orforglipron is expected to have favorable stability characteristics compared to peptide-based agents (no cold chain requirement anticipated, though final specifications are pending). Commercial formulation and storage conditions have not been finalized.
References
- 1RCT
Orforglipron, an Oral Non-peptide GLP-1 Receptor Agonist, in Obesity (Phase 2)
Wharton S, Blevins T, Connery L, et al. (2023). New England Journal of Medicine
Key findings: Phase 2 RCT in 272 adults with overweight/obesity without T2D. Dose-dependent weight loss of up to 14.7% at 36 weeks. Oral administration with no food or water restrictions.
Limitations: Phase 2 study. 36-week duration. GI tolerability was the most common AE.
View source - 2RCT
Oral Orforglipron for Type 2 Diabetes (Phase 2)
Frias JP, Hsia S, Eyde S, et al. (2023). New England Journal of Medicine
Key findings: Phase 2 trial in 383 adults with T2D. Orforglipron achieved HbA1c reductions of up to 2.1% and weight loss of up to 7.9 kg at 26 weeks. No fasting or water restriction required, unlike oral semaglutide.
Limitations: Phase 2. Short duration (26 weeks). Multiple dose arms with small per-group sample sizes.
View source - 3review
Small-Molecule GLP-1 Receptor Agonists: The Future of Oral Incretin Therapy
Pratley RE, Bhatt DL. (2024). Diabetes Care
Key findings: Review of the development of oral non-peptide GLP-1RAs. Discusses the advantages of small molecules over oral peptide formulations including no fasting requirements, improved bioavailability, and potential for lower cost of manufacturing.
Limitations: Narrative review. Phase 3 data not yet available at time of publication.
Last reviewed: 2026-03-24 | Version: 1 | Status: Published
More in Metabolic/GLP-1
Retatrutide
LY3437943 · Reta
Retatrutide is an investigational weight loss medication that works on three different hormone pathways at once. In clinical trials, people lost an average of about 24% of their body weight over 48 weeks, which is more than currently available medications achieve. It is still being studied and has not yet been approved by the FDA.
Cagrilintide
NN9838 · AM833
Cagrilintide is an investigational medication that mimics a natural hormone called amylin, which helps you feel full after eating. It is being developed as a once-weekly injection for weight management. It is also being studied in combination with semaglutide (a GLP-1 medication) under the name CagriSema, which may produce greater weight loss than either drug alone.
CagriSema
Cagrilintide + Semaglutide · NNC9204-1706 + NNC9204-0530
CagriSema combines two medications in a single weekly injection: semaglutide (which works on the GLP-1 pathway) and cagrilintide (which works on the amylin pathway). By targeting two different hunger-related hormone systems at once, it may produce greater weight loss than either medication alone. It is currently in late-stage clinical trials.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider